HMP Global
Oncology Learning Network
Podcast by HMP Global
Be sure to visit the podcast's website and support the creator: soundcloud.com
Where to listen?
Podcasts in the app Replaio Radio Coming soonPodcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts
Episodes
Dr Abou-Alfa Discusses POLO Trial, Olaparib to Treat gBRCA-mutated, Metastatic Pancreatic Cancer 03.01.2020 2:49
Recapping a late-breaking abstract from ASCO 2019, Dr Abou-Alfa discusses POLO Trial, Olaparib to Treat gBRCA-mutated, Metastatic Pancreatic Cancer. Since the recording of this podcast, olaparib has been approved by the FDA as maintenance therapy for gBRCA-mutated metastatic pancreatic cancer as of December 30, 2019.
Effect of Cost on Adherence to Therapy in Patients With Breast Cancer 30.12.2019 3:32
Dawn Hershman, MD, MS, Professor of Medicine and Epidemiology at Columbia University Medical Center, Herbert Irving Comprehensive Cancer Center, New York, discusses how the cost of breast cancer treatment is directly associated with rates of adherence, and explains why financial factors matter in treatment decisions.
Encouraging Clinical Trial Participation in Patients With Cancer 18.12.2019 1:35
Shanu Modi, MD, Memorial Sloan Kettering Cancer Center, New York, talks about the benefits of clinical trial participation for patients with cancer.
Updates in the HER2 Breast Cancer Therapy Space - Part I 18.12.2019 4:05
Shanu Modi, MD, Memorial Sloan Kettering Cancer Center, New York, talks about the latest data being presented on HER2 breast cancer therapy options.
Updates in the HER2 Breast Cancer Therapy Space - Part II 18.12.2019 1:47
Shanu Modi, MD, Memorial Sloan Kettering Cancer Center, New York, talks about the latest data being presented on HER2 breast cancer therapy options.
Shanu Modi, MD, Discusses the DESTINY-Breast01 Trial 18.12.2019 4:00
Dr Modi discusses the basis, clinical significance, and findings of the DESTINY-Breast04 trial of DS-8201a therapy for HER2-low breast cancer.
Novel BTK Inhibitor Shows Promising for Mantle Cell Lymphoma 17.12.2019 5:03
Novel BTK Inhibitor Shows Promising for Mantle Cell Lymphoma by HMP Global
DS-8201a Shows Promise in Treatment of HER2-Positive Breast Cancer 12.12.2019 1:11
Sherene Loi, MD, PhD, Consultant Medical Oncologist, Peter MacCallum Cancer Centre, Melbourne, Australia, spoke with Oncology Learning Network about data that was presented regarding the use of DS-8201a in the treatment of HER2-positive breast cancer.
Treating Early Stage, HER2-Positive Breast Cancer 12.12.2019 2:22
Sherene Loi, MD, PhD, Consultant Medical Oncologist, Peter MacCallum Cancer Centre, Melbourne, Australia, talks about advancements made in the treatment of patients with early stage, HER2-positive breast cancer.
The Promising Role of Tucatinib in HER2-Positive Breast Cancer Therapy 12.12.2019 1:41
Sherene Loi, MD, PhD, Consultant Medical Oncologist, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the HER2CLIMB study and the promising role of tucatinib in the treatment of metastatic, HER2-positive breast cancer.
Evolution of the treatment landscape for Tenosynovial Giant Cell Tumors 21.11.2019 3:43
Jonathan Trent, MD, PhD, Professor and Associate Director for Clinical Research, Sylvester Comprehensive Cancer Center, University of Miami, Florida discusses the evolution of the current treatment landscape for tenosynovial giant cell tumors.
Pexidartinib Demonstrates Great Tumor Response in Tenosynovial Giant Cell Tumors 08.11.2019 5:19
Pexidartinib Demonstrates Great Tumor Response in Tenosynovial Giant Cell Tumors by HMP Global
Niraparib After First-Line Chemotherapy New Standard of Care for Advanced Ovarian Cancer 29.10.2019 5:31
Niraparib After First-Line Chemotherapy New Standard of Care for Advanced Ovarian Cancer by HMP Global
Amer Zeidan, MBBS, MHS, discusses Myelodysplastic Syndrome(MDS)at 2019 ASH MHM 24.10.2019 16:41
Amer Zeidan, MBBS, MHS, Yale University, discusses diagnosis and treatment of Myelodysplastic Syndrome(MDS)at 2019 ASH Meeting on Hematologic Malignancies
Newer Treatment Options for Patients With Hodgkin Lymphoma 18.10.2019 5:55
Newer Treatment Options for Patients With Hodgkin Lymphoma by HMP Global
Treating Newly Diagnosed Patients With MCL 17.10.2019 8:32
Treating Newly Diagnosed Patients With MCL by HMP Global
FOxTROT Trial Supports Preoperative Chemotherapy in Colon Cancer, with Matthew Seymour, MD 01.10.2019 19:17
Matthew Seymour, MD, discusses the FOxTROT trial that supports preoperative chemotherapy as a treatment with multiple, clear benefits for patients with colon cancer.
Isatuximab Triplet Encouraging for Relapsed/Refractory Multiple Myeloma 12.09.2019 9:32
Isatuximab Triplet Encouraging for Relapsed/Refractory Multiple Myeloma by HMP Global
Neratinib Plus Capecitabine Improves PFS in HER2-Positive Breast Cancer 31.07.2019 5:15
Neratinib Plus Capecitabine Improves PFS in HER2-Positive Breast Cancer by HMP Global
Adding Ribociclib to Endocrine Therapy Improves OS in Young Patients With Advanced Breast Cancer 19.06.2019 6:20
Sara A. Hurvitz, MD, University of California-Los Angeles Jonsson Comprehensive Cancer Center, discusses the background, findings, and clinical significance of the MONALEESA 7 trial, the findings of which were presented at the 2019 ASCO Annual Meeting.
Ixazomib Promising Maintenance Therapy Option for Multiple Myeloma 11.04.2019 2:02
Ixazomib Promising Maintenance Therapy Option for Multiple Myeloma by HMP Global
Novel Immunotherapy Approaches for Multiple Myeloma 11.04.2019 7:21
Novel Immunotherapy Approaches for Multiple Myeloma by HMP Global
Earlier Daratumamab Use Feasible for Relapsed/Refractory Multiple Myeloma 11.04.2019 7:21
Earlier Daratumamab Use Feasible for Relapsed/Refractory Multiple Myeloma by HMP Global
Survey Results Show Oncologists Want to Learn More About the Needs of LGBTQ Patients 04.04.2019 10:34
Matthew B. Schabath, PhD, discusses the results of his team’s national survey, which was conducted to identify potential gaps in attitudes, knowledge, and institutional practices toward LGBTQ patients with cancer.
Daunorubicin Decreases Long-Term Cardiomyopathy Risk in Childhood Cancer Survivors 12.03.2019 10:58
Daunorubicin Decreases Long-Term Cardiomyopathy Risk in Childhood Cancer Survivors by HMP Global
Similar podcasts
Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.